The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses
Authors
Keywords
Acute myeloid leukemia, AML, CRh, CRi, CRp, Incomplete, Partial, Remission, Response
Journal
BLOOD REVIEWS
Volume 48, Issue -, Pages 100806
Publisher
Elsevier BV
Online
2021-01-29
DOI
10.1016/j.blre.2021.100806
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy
- (2019) Areej El-Jawahri et al. LEUKEMIA
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
- (2019) Rory M. Shallis et al. BLOOD REVIEWS
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
- (2019) Daniel A. Pollyea et al. LEUKEMIA
- Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)
- (2019) Mary-Elizabeth M. Percival et al. BLOOD
- The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia
- (2019) Rory M. Shallis et al. BLOOD REVIEWS
- How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
- (2019) Brian A. Jonas et al. LEUKEMIA
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia
- (2019) Jan Philipp Bewersdorf et al. BLOOD REVIEWS
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Time to repeal and replace response criteria for acute myeloid leukemia?
- (2018) Clara Derber Bloomfield et al. BLOOD REVIEWS
- Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
- (2018) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients
- (2018) Alexander Höllein et al. LEUKEMIA
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state
- (2018) Wen-Yan Cheng et al. Blood Cancer Journal
- Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
- (2018) Felicitas Thol et al. BLOOD
- Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
- (2018) Eytan M. Stein et al. BLOOD
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse
- (2017) P Boddu et al. LEUKEMIA
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The importance of erythroblast enumeration in myeloid neoplasia
- (2016) Amer M. Zeidan et al. ANNALS OF HEMATOLOGY
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
- (2016) M. R. Luskin et al. BLOOD
- Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia
- (2016) Shaun Fleming et al. BRITISH JOURNAL OF HAEMATOLOGY
- An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
- (2016) Paul Ferguson et al. HAEMATOLOGICA
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?
- (2016) Daisuke Araki et al. JOURNAL OF CLINICAL ONCOLOGY
- Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
- (2016) U Krug et al. LEUKEMIA
- An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
- (2016) Paul Ferguson et al. HAEMATOLOGICA
- Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
- (2015) Khoan Vu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
- (2015) Xueyan Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
- (2015) Juliette Lambert et al. Oncotarget
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
- (2013) Sylvain Thépot et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
- (2013) A. K. Burnett et al. BLOOD
- Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy
- (2012) E. Chendamarai et al. BLOOD
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
- (2012) J. A. L. Yin et al. BLOOD
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
- (2012) A K Burnett et al. LEUKEMIA
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
- (2010) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
- Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias
- (2009) H. B. Ommen et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia
- (2008) Masamitsu Yanada et al. LEUKEMIA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now